FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

TEMENT	OF CHA	VICES IV	I RENECICIAL	OWNEDSHI

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average I	burden						
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     PEPIN RONALD					2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [ CLDX ]							(Ch	elationship of eck all applica Director	able)	Perso	on(s) to Issu 10% Ow Other (s	ner	
(Last) (First) (Middle) C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD					3. Date of Earliest Transaction (Month/Day/Year) 06/13/2018								below)		below) VP & CBO		,	
(Street)			08827	4						Line	dividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person							
(City)	(S	state)	(Zip)															
		Та	ıble I - Non-I	Derivat	ive S	ecuritie	s Ad	cqui	red, Di	spos	sed of	f, or Be	neficiall	Owned				
Date			Transacti ate Month/Day	Execution Date,		Code (Instr.			5. Amoun Securities Beneficial Owned Fo Reported	Form (D) o		Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
					Code V Amount (A) or (D)				Price	Transaction(s) (Instr. 3 and 4)								
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	perivative Conversion Date Execution Date Execution Date or Exercise (Month/Day/Year) if any		Execution Date,	Code	ansaction Derivative ode (Instr. Securities		re s I (A) sed str.	Expiration Date (Month/Day/Year)		te	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exer	e rcisable	Expir Date	iration	Title	Amount or Number of Shares		(Instr. 4)			
Incentive Stock Option (right to buy) <sup>(1)</sup>	\$0.6011	06/13/2018		A		200,000		06/1	3/2019 <sup>(2)</sup>	06/13	3/2028	Common Stock	200,000	\$0	200,00	00	D	

## Explanation of Responses:

- $1. \ Represents option \ granted \ by \ the \ Issuer \ pursuant \ to \ its \ 2008 \ Stock \ Option \ and \ Incentive \ Plan.$
- $2.\,25\%\ vest\ on\ June\ 13,\,2019\ and\ the\ remainder\ vest\ quarterly\ (in\ equal\ amounts)\ over\ the\ subsequent\ 12\ quarters.$

/s/ Samuel B. Martin, attorney in fact for Ronald A. Pepin,

Ph.D.

\*\* Signature of Reporting Person

Date

06/15/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## **POWER OF ATTORNEY**

Know all by those present, that the undersigned hereby constitutes and appoints each of Samuel B. Martin and Anthony S. Marucci his true and lawful attorney-in-fact to:

- 1. execute for and on behalf of the undersigned Schedules 13D and 13G, Form ID, and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedules 13D or 13G, Form ID and Forms 3, 4 or 5, and the timely filing of such Forms with the United States Securities and Exchange Commission and any other authority; and
- 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, including without limitation the execution and filing of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as he might or could do in person, with full power of substitution and resubstitution, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of June, 2017.

<u>/s/ Ronald Pepin</u> Name: Ronald Pepin